• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 3:16:30 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GOVX alert in real time by email
    SC 13G/A 1 cavalry_geovax13g.htm SC 13G/A SC13G/A

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    SCHEDULE 13G


    Under the Securities Exchange Act of 1934

    (Amendment No. 1 )*


    GeoVax Labs, Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value

    (Title of Class of Securities)


    373678 309

    (CUSIP Number)



    January 22, 2021

    (Date of Event which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:


     

     Rule 13d-1(b)

     

     

    ü

     Rule 13d-1(c)

     

     

     

     Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

     




    CUSIP No. 373678 309                                             13G                                                  Page 2 of 6 Pages




    1

    NAME OF REPORTING PERSON


    Cavalry Fund I Management LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)   ¨

    (b)   ¨

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

     

    219,335 (1)

     

     

    6

    SHARED VOTING POWER (see Item 5 below)


    0

     

     

    7

    SOLE DISPOSITIVE POWER

     

    219,335 (1)

     

     

    8

    SHARED DISPOSITIVE POWER (see Item 5 below)


    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON


    219,335 (1)

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES


    þ (2)

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)


    4.99%

     

    12

    TYPE OF REPORTING PERSON


    OO

     





    CUSIP No. 373678 309                                             13G                                                  Page 3 of 6 Pages




    1

    NAME OF REPORTING PERSON


    Thomas Walsh

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)   ¨

    (b)   ¨

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

     

    219,335 (1)

     

     

    6

    SHARED VOTING POWER (see Item 5 below)


    0

     

     

    7

    SOLE DISPOSITIVE POWER

     

    219,335 (1)

     

     

    8

    SHARED DISPOSITIVE POWER (see Item 5 below)


    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON


    219,335 (1)

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES


    þ (2)

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)


    4.99%

     

    12

    TYPE OF REPORTING PERSON


    IN

     


    (1)

    Represents 219,335 shares of common stock issuable upon exercise of warrants (see footnote 2) held by Cavalry Fund I LP and Cavalry Special Ops Fund LLC, collectively. Cavalry Fund I Management LLC is the general partner of Cavalry Fund I LP and Cavalry Special Ops Fund LLC. Thomas Walsh is the Manager of Cavalry Fund I Management LLC. As such, Cavalry Fund I Management LLC and Mr. Walsh may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) 219,335 shares of common stock. To the extent Mr. Walsh is deemed to beneficially own such shares, Mr. Walsh disclaims beneficial ownership of these securities for all other purposes.

    (2)

    Cavalry Fund I LP and Cavalry Special Ops Fund LLC each owns warrants to purchase 215,035 shares of common stock (430,070 shares of common stock in total), only a portion of which are currently exercisable due to a beneficial ownership limitation of 4.99% of the Company’s issued and outstanding common stock.





    CUSIP No. 373678 309                                             13G                                                  Page 4 of 6 Pages




    Item 1(a).

    Name of Issuer

     

     

     

    GeoVax Labs, Inc. (“Issuer”)

     

     

    Item 1(b).

    Address of the Issuer’s Principal Executive Offices

     

     

     

    1900 Lake Park Drive, Suite 380, Smyrna, Georgia 30080

     

    Item 2(a).

    Names of Persons Filing

     

     

     

    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

     

    (i)

    Cavalry Fund I Management LLC

     

     

    (ii)

    Thomas Walsh

     

    Item 2(b).

    Address of the Principal Business Office, or if none, Residence:

     

     

     

    The address for each Reporting Person is 61 82 E. Allendale Rd. Ste 5B, Saddle River, NJ 07458.

     

     

    Item 2(c).

    Citizenship

     

     

    Cavalry Fund I Management LLC is a limited liability company formed under the laws of Delaware.

     

     

     

    Thomas Walsh is a citizen of the United States.

     

    Item 2(d).

    Title of Class of Securities

     

     

     

    Common Stock, $0.001 par value (“Common Stock”)

     

    Item 2(e).

    CUSIP Number

     

     

     

    373678 309


    Item 3.

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

     

    (a)  Broker or Dealer registered under Section 15 of the Exchange Act.

     

     

     

    (b) Bank as defined in Section 3(a)(b) or the Exchange Act.

     

     

     

    (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.

     

     

     

    (d) Investment company registered under Section 8 of the Investment Company Act.

     

     

     

    (e) An Investment adviser in accordance with Rule 13d-1 (b)(1)(ii)(e).

     

     

     

    (f)  An employee benefit plan or endowment fund in accordance with Rule 13d 1(b)(1)(ii)(f).

     

     

     

    (g) A Parent Holding Company or control person in accordance with Rule 13d 1(b)(1)(ii)(g).

     

     

     

    (h) A Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.

     

     

     

    (i) A Church Plan that is excluded from the definition of an investment company under Section 3 (c)(14) of the Investment Company Act.




    CUSIP No. 373678 309                                             13G                                                  Page 5 of 6 Pages




     

    (j) Group, in accordance with Rule 13d-1 (b)(1)(ii)(j).

     

     

     

    Not applicable


    Item 4.

    Ownership

     

     

    (a)

    The responses to Items 5-11 of the cover pages of this Schedule 13G/A are incorporated herein by reference.

     

     

    (b)

    The percentage set forth on Row (11) of the cover page for each Reporting Person is based on 4,395,458 shares of common stock outstanding as of January 25, 2021.

     

     

    (c)

    Cavalry Fund I Management LLC is the general partner of Cavalry Fund I LP and Cavalry Special Ops Fund LLC. Thomas Walsh is the Manager of Cavalry Fund I Management LLC. As such, Cavalry Fund I Management LLC and Mr. Walsh may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) 219,335 shares of common stock. To the extent Mr. Walsh is deemed to beneficially own such shares, Mr. Walsh disclaims beneficial ownership of these securities for all other purposes.

     

     

    (d)

    Cavalry Fund I LP and Cavalry Special Ops Fund LLC each owns warrants to purchase 215,035 shares of common stock (430,070 shares of common stock in total), only a portion of which is currently exercisable due to a beneficial ownership limitation of 4.99% of the Company’s issued and outstanding common stock.

     

    Item 5.

    Ownership of Five Percent or Less of a Class

     

     

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

     

     

     

    Not Applicable 

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

     

     

    Not Applicable

     

     

    Item 8.

    Identification and Classification of Members of the Group

     

     

     

    Not Applicable

     

     

    Item 9.

    Notice of Dissolution of Group

     

     

     

    Not Applicable

     

     

    Item 10.

    Certification

     

     

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.





    CUSIP No. 373678 309                                             13G                                                  Page 6 of 6 Pages



    SIGNATURE


    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.



     

    Cavalry Fund I Management LLC

     

     

     

     

     Date: February 10, 2021

    Thomas Walsh, as Manager of Cavalry Fund I Management LLC

     

     

     

     

    By:

    /s/ Thomas Walsh

     

     

    Name: Thomas Walsh

     

     

    Title: Manager

     

     

     

     Date: February 10, 2021

     

     

     

     

     

    By:

    /s/ Thomas Walsh

     

     

    Thomas Walsh

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     






    Get the next $GOVX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GOVX

    DatePrice TargetRatingAnalyst
    4/15/2025$18.00 → $14.00Buy
    D. Boral Capital
    4/15/2025$15.00 → $8.50Buy
    Alliance Global Partners
    11/11/2024$15.00Buy
    Alliance Global Partners
    7/16/2024$20.00Buy
    ROTH MKM
    More analyst ratings

    $GOVX
    SEC Filings

    See more
    • SEC Form 424B3 filed by GeoVax Labs Inc.

      424B3 - GeoVax Labs, Inc. (0000832489) (Filer)

      5/1/25 5:08:24 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by GeoVax Labs Inc.

      424B3 - GeoVax Labs, Inc. (0000832489) (Filer)

      5/1/25 5:06:58 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by GeoVax Labs Inc.

      424B3 - GeoVax Labs, Inc. (0000832489) (Filer)

      5/1/25 5:05:25 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

      SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

      11/14/24 5:10:48 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by GeoVax Labs Inc.

      SC 13G - GeoVax Labs, Inc. (0000832489) (Subject)

      2/14/24 3:38:25 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

      2/10/21 3:16:30 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spencer John N Jr bought $9,800 worth of shares (10,000 units at $0.98), increasing direct ownership by 713% to 11,402 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/11/25 1:23:33 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Business Development Sharkey John W. bought $5,940 worth of shares (6,000 units at $0.99), increasing direct ownership by 3,141% to 6,191 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/10/25 4:01:15 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO Dodd David A bought $10,800 worth of shares (10,000 units at $1.08), increasing direct ownership by 38% to 36,661 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/1/25 4:46:16 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $GOVX
    Leadership Updates

    Live Leadership Updates

    See more
    • Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

      MIAMI, April 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayApril 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to t

      4/16/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

      MIAMI, April 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 81th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1April 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already register

      4/15/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

      MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayMarch 26, 2025 11:00Virtual Lobby opens.Register for the Conference.  If you already registered, go back to

      3/26/25 7:00:00 AM ET
      $AEMD
      $ASPI
      $ATCH
      $BNRG
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

      Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vacci

      8/8/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

      Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company's Executive Medical Director, Oncology.  Kelly McKee, M.D., MPH, GeoVax Chief Medical Officer, commented, "Dr. Pipas' addition to our team represents an important step forward in the strengthening of GeoVax's organizational and operational resources to support advancement of our principal oncology asset, Gedeptin®, through clinical development

      1/8/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

      First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax. Dr. Montgomery Rice brings GeoVax exceptional expertise and highly recognized experience at the highest levels of healthcare leadership, patient care, biomedical resear

      12/20/22 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Financials

    Live finance-specific insights

    See more
    • GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

      Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end

      11/12/24 4:00:00 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

      GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call Details To access the live conference call, participants may register here. The live audio webcast of the call will be available

      11/5/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

      Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024;Gedeptin® to advance into expanded Phase 2 clinical trial with activation in the first half of 2025 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developin

      8/6/24 4:00:00 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spencer John N Jr bought $9,800 worth of shares (10,000 units at $0.98), increasing direct ownership by 713% to 11,402 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/11/25 1:23:33 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Business Development Sharkey John W. bought $5,940 worth of shares (6,000 units at $0.99), increasing direct ownership by 3,141% to 6,191 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/10/25 4:01:15 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO Dodd David A bought $10,800 worth of shares (10,000 units at $1.08), increasing direct ownership by 38% to 36,661 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/1/25 4:46:16 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital reiterated coverage on GeoVax Labs with a new price target

      D. Boral Capital reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $14.00 from $18.00 previously

      4/15/25 7:54:48 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners reiterated coverage on GeoVax Labs with a new price target

      Alliance Global Partners reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $8.50 from $15.00 previously

      4/15/25 7:54:17 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners initiated coverage on GeoVax Labs with a new price target

      Alliance Global Partners initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $15.00

      11/11/24 7:40:44 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care